Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | CCR9 | P51686 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3953382 | 0.88 | SSTR5 (0.44) | SSTR5ALDH1A1KMT2ARAB9AHTR3A | |
| SCHEMBL10073857 | 0.88 | SSTR5 (0.46) | SSTR5ALDH1A1LMNAHPGDTSHR | |
| SCHEMBL2208705 | 0.87 | SSTR5 (0.43) | SSTR5ALDH1A1KMT2ARAB9AHTR3A | |
| SCHEMBL2205523 | 0.86 | SSTR5 (0.42) | SSTR5ALDH1A1PKMRAB9AHTR3A | |
| SCHEMBL17437939 | 0.84 | ROCK1 (0.49) | SSTR5ALDH1A1PKMGAAKMT2A | |
| SCHEMBL3133312 | 0.83 | SSTR5 (0.43) | SSTR5ALDH1A1PKMHTR3A | |
| SCHEMBL3131958 | 0.83 | SSTR5 (0.46) | SSTR5ALDH1A1PKMKDM4EHPGD | |
| SCHEMBL492396 | 0.83 | ALDH1A1 (0.49) | ALDH1A1PKMGAAKMT2ALMNA | |
| SCHEMBL4014060 | 0.83 | SSTR5 (0.41) | SSTR5ALDH1A1PKMGAAHTR3A | |
| SCHEMBL10074429 | 0.82 | SSTR5 (0.44) | SSTR5ALDH1A1LMNAPTGER4HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237511-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK FROSST CANADA (CA) | 2011-09-29 | — | — | US | claimed |
| EP-1613621-B1 | PROSTAGLANDIN ANALOGS AS EP4 RECEPTOR AGONISTS | MERCK FROSST CANADA LTD (CA) | 2010-07-21 | — | — | EP | claimed |
| US-20090270395-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK & CO., INC. | 2009-10-29 | — | — | US | claimed |
| EP-1912957-A4 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | MERCK FROSST CANADA LTD (CA) | 2009-05-13 | — | — | EP | claimed |
| US-20090105234-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK & CO., INC. | 2009-04-23 | — | — | US | claimed |
| EP-1912957-A1 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | Merck Frosst Canada Ltd. (CA) | 2008-04-23 | — | — | EP | claimed |
| EP-1912977-A1 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | Merck Frosst Canada Ltd. (CA) | 2008-04-23 | — | — | EP | claimed |
| WO-2007014462-A1 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | MERCK FROSST CANADA LTD. (CA) | 2007-02-08 | — | — | WO | claimed |
| WO-2007014454-A1 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | MERCK FROSST CANADA LTD. (CA) | 2007-02-08 | — | — | WO | claimed |
| JP-2006520758-A | — | — | 2006-09-14 | — | — | JP | claimed |
| EP-1613621-A1 | PROSTAGLANDIN ANALOGS AS EP4 RECEPTOR AGONISTS | Merck Frosst Canada Ltd. (CA) | 2006-01-11 | — | — | EP | claimed |
| WO-2005116010-A1 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | MERCK FROSST CANADA LTD. (CA) | 2005-12-08 | — | — | WO | claimed |
| US-20050227969-A1 | EP4 receptor agonist, compositions and methods thereof | MERCK CANADA INC. (CA) | 2005-10-13 | — | — | US | claimed |
| WO-2004085430-A1 | PROSTAGLANDIN ANALOGS AS EP4 RECEPTOR AGONISTS | MERCK FROSST CANADA LTD. (CA) | 2004-10-07 | — | — | WO | claimed |
| WO-2004085431-A1 | PROSTAGLANDIN ANALOGS AS EP4 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2004-10-07 | — | — | WO | claimed |
| US-20040198701-A1 | EP4 receptor agonist, compositions and methods thereof | MERCK CANADA INC. (CA) | 2004-10-07 | — | — | US | claimed |
| US-20110237511-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | MERCK FROSST CANADA (CA) | 2011-09-29 | — | — | US | disclosed |
| US-RE42562-E1 | EP4 receptor agonist, compositions and methods thereof | MERCK FROSST CANADA (CA) | 2011-07-19 | — | — | US | disclosed |
| WO-2004085431-A1 | PROSTAGLANDIN ANALOGS AS EP4 RECEPTOR ANTAGONISTS | MERCK FROSST CANADA LTD. (CA) | 2004-10-07 | — | — | WO | disclosed |
| WO-2004085430-A1 | PROSTAGLANDIN ANALOGS AS EP4 RECEPTOR AGONISTS | MERCK FROSST CANADA LTD. (CA) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198701-A1 | EP4 receptor agonist, compositions and methods thereof | PTGER4, PTGER1, PTGER3 | SSTR5 540/4885ALDH1A1 3096/4885PKM 2057/4885 |
| US-20090270395-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | PTGER4, PTGER1, PTGER3 | SSTR5 482/4885ALDH1A1 2261/4885PKM 1937/4885 |
| US-20110237511-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | PTGER4, PTGER1, PTGER3 | SSTR5 553/4885ALDH1A1 3109/4885PKM 2089/4885 |
| US-20090105234-A1 | EP4 Receptor Agonist, Compositions and Methods Thereof | PTGER4, PTGER1, PTGER3 | SSTR5 553/4885ALDH1A1 3109/4885PKM 2089/4885 |
| US-20050227969-A1 | EP4 receptor agonist, compositions and methods thereof | PTGER4, PTGER1, PTGER3 | SSTR5 553/4885ALDH1A1 3109/4885PKM 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.